Indications

• Peritoneal Mesothelioma (see xxxx, [[xxxx]])
• Pleural Mesothelioma (see Mesothelioma, [[Mesothelioma]]): FDA-approved in 2004
• Non-Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]]): FDA-approved in 2008
  • PARAMOUNT Trial

---

Pharmacology

• Folate Anti-Metabolite: inhibition of enzymes used in purine/pyrimidine synthesis -> inhibits RNA/DNA synthesis
  • Inhibition Thymidylate Synthase
  • Inhibition of Dihydrofolate Reductase
  • inhibition of Glycinamide Ribonucleotide Formyltransferase

Metabolism

• xxxx

---

Administration

• xxx

Dose Adjustment

• xxxx

---

Adverse Effects

Hematologic Adverse Effects

• Megaloblastic Anemia (see Anemia, [[Anemia]])

Other Adverse Effects

• xxx

---

References

• xxx